Scleroderma natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Scleroderma}} | {{Scleroderma}} | ||
{{CMG}} | |||
{{CMG}}; {{AE}} {{MKA}} | |||
==Overview== | ==Overview== | ||
==Natural History== | If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | ||
==Complications== | |||
OR | |||
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3]. | |||
OR | |||
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%. | |||
==Natural History, Complications, and Prognosis== | |||
===Natural History=== | |||
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___. | |||
*The symptoms of (disease name) typically develop ___ years after exposure to ___. | |||
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | |||
===Complications=== | |||
*Common complications of scleroderma include:<ref name="pmid22269658">{{cite journal |vauthors=Barnes J, Mayes MD |title=Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers |journal=Curr Opin Rheumatol |volume=24 |issue=2 |pages=165–70 |date=March 2012 |pmid=22269658 |doi=10.1097/BOR.0b013e32834ff2e8 |url=}}</ref> | |||
**Scleroderma renal crisis | |||
**Pulmonary fibrosis | |||
**Pulmonary arterial hypertension | |||
**Malignancy | |||
===Prognosis=== | |||
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%. | |||
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | |||
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | |||
*[Subtype of disease/malignancy] is associated with the most favorable prognosis. | |||
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
{{ | [[Category: (name of the system)]] | ||
{{ | |||
Revision as of 19:23, 28 March 2018
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Scleroderma natural history, complications and prognosis |
|
FDA on Scleroderma natural history, complications and prognosis |
|
CDC on Scleroderma natural history, complications and prognosis |
|
Scleroderma natural history, complications and prognosis in the news |
|
Blogs on Scleroderma natural history, complications and prognosis |
|
Risk calculators and risk factors for Scleroderma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of scleroderma include:[1]
- Scleroderma renal crisis
- Pulmonary fibrosis
- Pulmonary arterial hypertension
- Malignancy
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
- Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Barnes J, Mayes MD (March 2012). "Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers". Curr Opin Rheumatol. 24 (2): 165–70. doi:10.1097/BOR.0b013e32834ff2e8. PMID 22269658.